Overview

Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

CASI Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Angiostatins
Carboplatin
Paclitaxel